Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
The Lancet. Oncology
|
March 31, 2004
Octreotide: an active agent in epithelial ovarian carcinoma?
Robert H Jones, Jean-Claude Reubi, David Millan, et al.
Urology
|
November 10, 2004
Management of renal masses in patients medically unsuitable for nephrectomy--natural history, complications, and outcome
Gavin W A Lamb, Emma J Bromwich, Paul Vasey, et al.
Journal of Medical Imaging and Radiation Oncology
|
November 7, 2025
What Do Medical Oncologists Expect From PET/CT Reports
Sepinoud Firouzmand, Paul Vasey, Louise McEwan, et al.
Investigative and Clinical Urology
|
November 3, 2021
Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
William John Yaxley, Rhiannon McBean, David Wong, et al.
British Journal of Clinical Pharmacology
|
July 10, 2003
A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979)
Sophie Callies, Dinesh P de Alwis, Adrian Harris, et al.
Gynecologic Oncology
|
December 4, 2010
Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma
Andreas Obermair, Linda Mileshkin, Katharina Bolz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 24, 2014
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
Sven Mahner, Werner Meier, Andreas du Bois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2007
18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group
Robert A Huddart, Michael J O'Doherty, Anwar Padhani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group
Graham G Dark, A Hilary Calvert, Robert Grimshaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2007
Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients
John F Smyth, Charlie Gourley, Graeme Walker, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
The Lancet. Oncology
|
March 31, 2004
Octreotide: an active agent in epithelial ovarian carcinoma?
Robert H Jones, Jean-Claude Reubi, David Millan, et al.
Urology
|
November 10, 2004
Management of renal masses in patients medically unsuitable for nephrectomy--natural history, complications, and outcome
Gavin W A Lamb, Emma J Bromwich, Paul Vasey, et al.
Journal of Medical Imaging and Radiation Oncology
|
November 7, 2025
What Do Medical Oncologists Expect From PET/CT Reports
Sepinoud Firouzmand, Paul Vasey, Louise McEwan, et al.
Investigative and Clinical Urology
|
November 3, 2021
Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?
William John Yaxley, Rhiannon McBean, David Wong, et al.
British Journal of Clinical Pharmacology
|
July 10, 2003
A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979)
Sophie Callies, Dinesh P de Alwis, Adrian Harris, et al.
Gynecologic Oncology
|
December 4, 2010
Prospective, non-randomized phase 2 clinical trial of carboplatin plus paclitaxel with sequential radical pelvic radiotherapy for uterine papillary serous carcinoma
Andreas Obermair, Linda Mileshkin, Katharina Bolz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 24, 2014
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
Sven Mahner, Werner Meier, Andreas du Bois, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 20, 2007
18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group
Robert A Huddart, Michael J O'Doherty, Anwar Padhani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group
Graham G Dark, A Hilary Calvert, Robert Grimshaw, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2007
Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients
John F Smyth, Charlie Gourley, Graeme Walker, et al.
Page
of 2